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Abstract
Background: The nomogram of the Barcelona Clinic Liver Cancer (BCLC) for hepatocellular carcinoma (HCC) has
been used for outcome prediction. Patients with BCLC stage C HCC often undergo anti-cancer therapy against
current treatment guidelines in real world practice. We aimed to use the nomogram to provide guidance on
treatment selection for BCLC stage C patients.
Methods: A total of 1317 patients with stage C HCC were retrospectively analyzed and divided into four groups by
nomogram points. One-to-one matched pairs between patients receiving different treatments were generated by
the propensity score with matching model within these groups. Survival analysis was performed by Kaplan-Meier
method with log-rank test.
Results: Patients with higher nomogram points were more often treated with targeted or supportive therapies (p < 0.
001). Patients receiving targeted or supportive therapies had a decreased survival compared to patients undergoing
aggressive treatments (surgical resection, ablation, transarterial chemo-embolization or transplantation) across all four
groups (p < 0.001). After matching for baseline differences in the propensity model, patients receiving different
treatments had comparable age, gender, etiology of liver disease, tumor burden, severity of cirrhosis and performance
status. Survival analyses were re-performed and disclosed that patients with nomogram points < 15 had better overall
outcome after aggressive treatments (p < 0.05). For patients with nomogram points > 15, there was no significant
difference in survival between patients receiving two different treatment strategies.
Conclusions: The nomogram of BCLC system is a feasible tool to help stage C HCC patients to select primary
anti-cancer treatment in pursuance of better overall survival.
Keywords: Barcelona clinic liver Cancer, Hepatocellular carcinoma, Nomogram, Staging system
Background
Hepatocellular carcinoma (HCC) is one of the most com-
mon cancers in the world. The Barcelona Clinic Liver
Cancer (BCLC) staging system has been recommended to
be the prognostic model and also the allocating tool of
primary anti-cancer treatment by major academic
societies for liver diseases [1, 2]. For patients with BCLC
stage C HCC, targeted therapy (sorafenib) has been sug-
gested as the treatment of choice after two large random-
ized studies were published [3, 4]. However, a substantial
proportion of patients may select more aggressive anti-
cancer treatments to prolong their survival [5, 6]. Alterna-
tively, it is also conceivable that patients receiving aggres-
sive therapies could have a higher risk of treatment-
associated complications that may sometimes lead to a
shortened survival [7]. Currently, there is no clear
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consensus to suggest patients with BCLC stage C to re-
ceive more aggressive treatments instead of targeted
therapy.
Recently, the nomogram of the BCLC system, which is
designed to provide individualized prediction of patient
survival, has been proposed and externally validated [8–
10]. By using well-known clinical parameters of the BCLC
system (performance status [PS], tumor burden and sever-
ity of cirrhosis), there is no additional lab test or compli-
cated mathematic equation required to use this tool. The
nomogram can also further stratify HCC patients within
the same BCLC stage into multiple levels to reflect differ-
ent disease severity, and may be helpful to design an opti-
mal treatment strategy in real-world practice. This study
aims to specifically investigate if aggressive treatments
(surgical resection, transplantation, ablation and transar-
terial chemoembolization [TACE]) can improve the long-
term prognosis of patients with BCLC stage C HCC. Also,
the nomogram of BCLC is applied to provide better prog-
nostic stratification and to facilitate the selection of treat-
ment for stage C HCC patients.
Methods
Patients
During a 14-year period between 2002 and 2016, 1317
newly diagnosed BCLC stage C HCC patients in our hos-
pital were identified and retrospectively analyzed in this
study. Etiology of underlying liver disease, serum bio-
chemistry, number and size of tumor(s), PS, severity of
liver cirrhosis and cancer stage were comprehensively re-
corded at the time of diagnosis. The survival status of all
patients was checked every 2–3 months after enrollment
and was confirmed by using the database of National
Cancer Registry, Taiwan. This study has been approved by
the institutional review board (IRB) of Taipei Veterans
General Hospital. Before analysis, waiver of consent form
from each patient was obtained as justified by the IRB,
and patient information was blinded and de-identified.
Diagnosis and definitions
Findings of typical radiological features in at least two im-
aging modalities including magnetic resonance imaging
(MRI), contrast-enhanced dynamic computed tomography
(CT), ultrasound and hepatic arterial angiography, or by a
single positive imaging study associated with serum α-
fetoprotein (AFP) level ≥ 400 ng/mL or histological con-
firmation were used to diagnose HCC [11]. Daily consump-
tion of at least 40 g of alcohol for 5 years or more was
considered alcoholic liver disease [12]. Patients who were
seropositive for anti-hepatitis C virus (HCV) antibody were
classified as HCV-related HCC. Hepatitis B virus (HBV)-re-
lated HCC was defined as seropositive for HBsAg. Vascular
invasion was diagnosed by the presence of thrombus adja-
cent to the tumor in portal system by at least two imaging
modalities. Total tumor volume was calculated based on
tumor diameter of every HCC nodules [13]. The Eastern
Cooperative Oncology Group (ECOG) criteria were used to
evaluate the overall physical status of each patient [14]. Pa-
tients with single tumor smaller than 2 cm in size were
coded as tumor burden grade 0. Patients with tumor bur-
den beyond grade 0 and within the Milan criteria (one nod-
ule < 5 cm, up to 3 nodules < 3 cm, no vascular invasion or
extrahepatic involvement) were classified as tumor burden
grade 1 [10, 15]. Patients were recorded as tumor burden
grade 3 if lymph node involvement, vascular invasion, or
distant metastasis were confirmed at the time of diagnosis.
All remaining patients were coded as tumor burden grade
2 [10]. Chest CT scan was performed to detect metastatic
lesion(s) and lymph node involvement. Bone metastasis of
HCC was surveyed by bone scan and confirmed by MRI if
indicated. Surgical resection, ablation, liver transplantation
and TACE were collectively defined as aggressive treat-
ments, and targeted therapy and supportive treatment were
classified together as the reference group based on the ori-
ginal design of BCLC system. All clinical data were re-
corded at the time of diagnosis before specific anti-cancer
therapy was performed.
Treatment
General criteria of surgical resection were (1) patients
with tumor involving no more than 3 Healey’s segment,
(2) Child-Turcotte-Pugh (CTP) class A, and (3) no main
portal vein trunk involvement or distant metastasis.
Liver transplantation was considered in patients fulfilling
the Milan criteria [15]. TACE was performed depending
on the size and number of tumor nodules as previously
reported [5, 7]. Seldinger’s technique of arterial
embolization was performed as the standard TACE pro-
cedure. After tumor stain was identified, infusion of a
mixture of 20–30 mg adriamycin (Carlo Erba, Milan,
Italy) and 5–10 mL Lipiodol (Laboratoire Guerbet, Ville-
pinte, France) was performed after the artery supplying
the tumor was catheterized superselectively. Sufficient
amount of emulsion and 2–3 mm strips of Gelfoam
(Upjohn, Kalamazoo, MI) were delivered to the tumor
area until complete flow stagnation was achieved.
Statistics
Continuous demographic characteristics were compared
with the Mann-Whitney ranked sum test. Categorical data
were compared with the chi-squared or Fisher exact tests.
The comparison of survival distributions was performed
by using the Kaplan-Meier method with a log-rank test. A
two-tailed p value less than 0.05 was considered statisti-
cally significant.
The propensity score was generated by using a logis-
tic regression, which calculated the possibility of each
patient to receive aggressive or targeted/supportive
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treatments. Possible variables associated with long-term
survival and treatments allocation, including age, gen-
der, severity of cirrhosis, PS, vascular invasion, tumor
burden, renal function, serum AFP level, diabetes melli-
tus were included comprehensively for propensity score
generation. To compare the association between ex-
perimental variable (anti-cancer treatment) and re-
sponse (survival), one-to-one pairs were selected by
using the propensity score and greedy algorithm to re-
duce potential biases in subsequent survival analysis
[16, 17]. The greedy algorithm used in this study per-
formed 5 to 1 digit matching mechanism; p-value and
standardized difference were used to evaluate the good-
ness of this propensity score with one-to-one matching
model. All statistical analyses were conducted with the
SAS 9.4 (SAS Institute Inc., Cary, NC, USA).
Results
Patient characteristics
The baseline patient characteristics are provided in Table 1.
Their mean age was 64 years, and 78% of them were male.
Hepatitis B (55%) was the most common etiology of
chronic liver disease. There were 41% patients who had
multiple tumors, and 64% of patients had a main tumor
diameter of more than 5 cm. Sixty-nine percent of pa-
tients were classified as CTP class A, and 24%, 53% and
23% of patients had PS 0, 1 and 2, respectively. Vascular
invasion was documented in 45% of patients, and 27% of
patients were diabetic. A total of 15% of patients were
confirmed with distant metastasis at study enrollment.
Of all patients, 21% of patients received partial hepa-
tectomy, and 0.3%, 11%, 33%, 8% and 26% of patients
underwent transplantation, ablation, TACE, targeted
therapy and best supportive care, respectively.
Distribution of nomogram points and primary anti-cancer
treatments
As shown in Fig. 1, nomogram points were assigned to all
enrolled patients by using PS, severity of cirrhosis and
tumor burden according to our recent study [10]. The
range of total nomogram points was between 3 (PS 1–2,
CTP class A and tumor burden 0) to 18.2 (PS 1–2, CTP
class B and tumor burden 3) for stage C patients (Fig. 2).
Ninety-five percent of patients with 3 points underwent ag-
gressive treatments, and 82% of patients with 18.2 points
received targeted/supportive therapies. Patients with more
advanced HCC had a significantly higher tendency to
receive targeted/supportive treatments (p < 0.001).
Characteristics of patients divided by nomogram points
Patients were divided by nomogram points into four
groups (total points: 3–4.2, 6.7–10, 11.9–13, 15.2–18.2).
Comparisons of baseline characteristics between patients
receiving aggressive and targeted/supportive treatments
within these four groups are given in Table 2. Within each
group, patients receiving different treatments had similar
distributions of age, gender, etiology of chronic liver dis-
ease and prevalence of diabetes mellitus (all p > 0.05), but
significant differences in tumor burden, PS, and severity
of cirrhosis were found among patients undergoing differ-
ent forms of treatment within these four groups (p < 0.05).
Comparison of survival between patients receiving
different treatments stratified by nomogram points
Within all four groups, patients receiving aggressive treat-
ments had significantly better overall survival compared to
Table 1 Baseline demographics of study patients
Number of patients 1317
Age (years, mean ± standard deviation [SD]) 64 ± 13
Male/female (%) 78/22
Etiology of cirrhosis (%)
Hepatitis B 721 (55)
Hepatitis C 349 (27)
Alcoholism 308 (23)
Serum biochemistry (mean ± SD)
Albumin (g/dL) 3.6 ± 0.6
Bilirubin (mg/dL) 1.4 ± 2.2
Creatinine (mg/dL) 1.2 ± 1.3
Estimated glomerular filtration rate (ml/min/
1.73m2)
78 ± 36
International normalized ratio of prothrombin
time
1.1 ± 0.1
Child-Turcotte-Pugh class A/B (%) 69/31
Number and size of tumor (%)
Single/multiple 59/41
≤ 5 cm/ > 5 cm 36/64
Total tumor volume (cm3, mean ± SD [median]) 566 ± 861 (193)
Vascular invasion (%) 591 (45)
Metastasis/lymph node 198 (15)
α-fetoprotein (ng/mL, mean ± SD [median]) 34,136 ± 177,031
(118)
Tumor burden 0/1/2/3 (%) 4.5/17.2/28.3/50
Ascites (%) 398 (30)
Performance status 0/1/2 (%) 24/53/23
Diabetes mellitus (%) 358 (27)
Treatment modality (%)
Resection 282 (21)
Transplantation 4 (0.3)
Ablation 149 (11)
Transarterial chemo-embolization 437 (33)
Targeted therapy 107 (8)
Best supportive care 338 (26)
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patients receiving targeted/supportive therapies (all p <
0.05; Fig. 3).
Characteristics of patients in the propensity model
divided by nomogram points
By using the propensity model, 15, 87, 112 and 45 pairs
of matched HCC patients were selected for the four
groups with absolute differences in propensity score of
matched pairs of < 0.0001, 0.0007, 0.0007 and < 0.0001,
respectively (Table 3). Among matched patients stratified
by the nomogram points, there were no significant dif-
ferences in gender, etiology of chronic liver disease, se-
verity of cirrhosis, number and size of tumor, PS, and
prevalence of diabetes mellitus (all p > 0.05). The major-
ity of standardized differences of significant prognostic
variables (e.g., tumor burden, cirrhosis, and PS) were
controlled under 0.2; some standardized differences in
group 1 (nomogram points: 3–4.2) and 4 (nomogram
points 15.2–18.2) were larger than 0.2.
Comparison of survival between patients receiving
different treatments stratified by nomogram points in the
propensity model
For patients with nomogram points 3–4.2, 6.7–10 and
11.9–13, aggressive treatments were associated with sig-
nificantly better survival (all p < 0.05). For patients with
nomogram points 15.2–18, there were no significant dif-
ferences in long-term survival after all variables were
controlled by the propensity model (p > 0.05; Fig. 4).
Discussion
Patients with advanced (BCLC stage C) HCC usually
have remarkably complex compositions. As such, indi-
vidualized treatment strategy by a multidisciplinary team
has been encouraged. The benefits of aggressive treat-
ments for patients with advanced HCC have been re-
ported by quite a few studies [18, 19]. In this study, we
investigated a large patient cohort to provide objective
and quantitative recommendations to help patients and
physicians to decide if aggressive treatments might be
helpful to prolong overall survival. By applying our re-
cently proposed BCLC nomogram, we have disclosed an
easy-to-use cutoff to identify patients with BCLC stage
C who can potentially benefit from aggressive treat-
ments. This finding also has important clinical implica-
tions because our results may help avoid unnecessary
treatment associated severe complications.
The BCLC staging system is mainly determined by
tumor burden, severity of cirrhosis and PS. For BCLC
stage C, PS 1–2 and tumor burden 3 (lymph node involve-
ment, vascular invasion, or distant metastasis) are suffi-
cient criteria, and CTP class C cirrhosis is only the
exclusion criterion regarding the severity of cirrhosis.
Therefore, the design of BCLC system results in a very
heterogeneous composition of BCLC stage C patients [6].
For example, a patient with a single small nodule, minimal
Fig. 1 The nomogram is used by adding up the points identified on the scales of these three parameters. BCLC stage C HCC patients have
nomogram points between 3 to 18.2
Fig. 2 Distribution of nomogram points and percentages of patients
receiving aggressive and targeted/supportive treatments. Patients
with higher nomogram points are more likely to receive targeted/
supportive therapies (p < 0.001)
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cirrhosis and PS 1 is classified as BCLC stage C, the same
cancer stage as a patient with large tumors, vascular inva-
sion, CTP class B cirrhosis and PS 2; these patients gener-
ally have highly variable clinical course and prognosis. The
nomogram of BCLC assigned points from 3 to 18 to pa-
tients with BCLC stage C and predicted their 3-year sur-
vival rate from approximately 80% to 10%, respectively
[10]. These findings underscore how diverse this patient
population is, and justify the necessity of treatment plan-
ning on an individual basis. The percentages of aggressive
and targeted/supportive treatments (Fig. 2) in our study
clearly showed that patients with smaller tumor burden,
less severe cirrhosis, and better physical condition were
more likely to undergo aggressive therapies, indicating in-
dividualized treatment strategy has been applied in the
daily practice.
We further split study patients into four groups (ap-
proximately one-quarter in each) by the nomogram
points to specifically investigate the prognostic effect of
aggressive treatments. In these four groups, patients re-
ceiving different therapies (aggressive vs. targeted/sup-
portive) had similar baseline characteristics including
age, gender, etiology of chronic liver disease and preva-
lence of diabetes mellitus at enrollment. On the other
hand, several significant differences of treatment
allocation-related variables (including severity of cirrho-
sis, tumor burden, and PS) were found between patients
receiving different treatments among the four groups,
suggesting therapeutic strategy is highly variable even
when patients have very similar nomogram points.
Notably, patients undergoing aggressive treatments
had significantly better outcome compared to patients
undergoing targeted/supportive treatments in this study;
however, patients who received aggressive treatments
more often had favorable baseline characteristics and
discreetly selected by the multidisciplinary team. There-
fore, we calculated propensity scores and performed
one-to-one match to minimize the confounding effects
of baseline differences, and introduced matched pairs of
patients into survival analyses again. With the propensity
model, matched pairs of patients were selected from the
four groups, and all the survival-related variables were
comparable. Survival analyses using paired matches of
patients showed that patients with nomogram points less
than 15 could benefit from aggressive treatments. Alter-
natively, for patients with more advanced BCLC stage C
HCC (nomogram points > 15), there was no significant
difference in survival between aggressive and targeted/
supportive treatment groups.
Fig. 3 Patients receiving aggressive treatments had significantly
better overall survival compared to patients receiving targeted/
supportive treatments across four groups divided by nomogram
points (all p < 0.05)
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For BCLC stage C patients with relatively favorable
characteristics (PS 1, CTP class A or no cirrhosis, and
smaller tumor burden), patients and physicians tend to
choose more aggressive forms of treatment. Surgical re-
section is reported to prolong survival for patients with
advanced yet resectable HCCs [5, 20], and ablation has
been administered in selected patients beyond the Milan
criteria [21]. Moreover, TACE has been associated with
improvement of overall survival compared to targeted
therapy [18]. All these studies support the idea of more
aggressive managements for patients with advanced
HCC [22, 23]. Also, our previous studies showed that
patients with PS 1 and 2 could have increased survival
after aggressive treatments [6, 24]. Altogether, targeted
therapy might not be the optimal treatment choice for
all BCLC stage C HCC patients. Importantly, our find-
ings from the propensity model not only support the
benefits of individualized treatments but also provide an
easy-to-use cutoff nomogram point to help patients on
treatment selection when taking potential complications
of aggressive treatments into consideration.
This study has some limitations. Firstly, aggressive treat-
ments could have differential survival impact to some ex-
tent. Similarly, patients receiving targeted therapy or
supportive treatment may have different survival distribu-
tion, and further studies are required to clarify this issue
[25, 26]. Secondly, only four patients in this study received
liver transplantation. Therefore the prognostic effect of
transplantation for BCLC stage C patients might not be ac-
curately evaluated [27, 28]. Thirdly, multiple studies re-
cently published promising results regarding the use of
immunotherapy to prolong overall survival of HCC pa-
tients; the application of immunotherapy is not addressed
in this study [29, 30]. Lastly, some patients underwent mul-
tiple sessions of anti-cancer treatment, but its effect was
not taken into account in this study. The prognostic effect
of follow-up treatment warrants future investigations.
Conclusions
In conclusion, this study indicates that the nomogram of
BCLC could provide useful stratification for patients with
advanced HCC. By applying the nomogram in our large
patient cohort, the distribution of individualized treatment
based on disease severity can be clearly specified. With
the propensity score matching model, we propose an
easy-to-use cutoff nomogram point to facilitate treatment
decision, avoid unnecessary medical interventions, and
improve overall survival in patients with advanced HCC.
Fig. 4 With the propensity score matching model, patients receiving
aggressive treatments had significantly better survival when nomogram
points were less than 15 (p< 0.05). For patients with nomogram more
than 15, there was no significant difference in survival between patients
receiving aggressive and targeted/supportive therapies (p> 0.05)
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